Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection
Background Reports of hepatitis B virus (HBV) reactivation in solid tumors are very limited, and their frequencies and risk factors were previously unknown. Aim To evaluate the prevalence and risk factors of HBV reactivation in patients with solid tumors with resolved HBV infection. Methods All 1088...
Gespeichert in:
| Veröffentlicht in: | Asia-Pacific journal of clinical oncology 2019-02, Vol.15 (1), p.63-68 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 68 |
|---|---|
| container_issue | 1 |
| container_start_page | 63 |
| container_title | Asia-Pacific journal of clinical oncology |
| container_volume | 15 |
| creator | Kotake, Takeshi Satake, Hironaga Okita, Yoshihiro Hatachi, Yukimasa Hamada, Mamiko Omiya, Masatomo Yasui, Hisateru Hashida, Toru Kaihara, Satoshi Inokuma, Tetsuro Tsuji, Akihito |
| description | Background
Reports of hepatitis B virus (HBV) reactivation in solid tumors are very limited, and their frequencies and risk factors were previously unknown.
Aim
To evaluate the prevalence and risk factors of HBV reactivation in patients with solid tumors with resolved HBV infection.
Methods
All 1088 patients with solid tumors were assessed for eligibility; 251 patients had resolved HBV infection (negative for HBs antigen and positive for anti‐HBc antibody and/or positive for anti‐HBs antibody), and HBV‐DNA was assessed for 243 of these patients in whom we analyzed the prevalence of HBV reactivation. Risk factors for HBV reactivation were exploratorily evaluated by analysis of a case–control study.
Results
The prevalence of HBV‐DNA reactivation was 2.1% (95% confidence interval [CI], 0.3–3.9%). We did not observe any exacerbation of HBV‐DNA by early intervention. A low anti‐HBs antibody titer (1.0 mg/day) were high risk factors, with odds ratios of 5.94 (95% CI, 1.15–30.6, P = 0.03) and 8.69 (95% CI, 1.27–58.8, P = 0.02), respectively.
Conclusion
HBV reactivation in solid tumor patients was relatively rare. Therefore, risk factors that can identify targets for HBV screening must be determined in future studies. |
| doi_str_mv | 10.1111/ajco.13050 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7379615</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2067132246</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4480-58b23bb46dba41e4332e16bd655a1fbd9c73862f12989398ecd6611934724ef73</originalsourceid><addsrcrecordid>eNp9kc1O3DAUhS3UCih0wwNUlrqpkAbi_3hTCUa0tEKCRdut5Tg3jIdMPLWTjHj7OgwdlS7wxtY53z261kHohBRnJJ9zu3ThjLBCFHvokCjOZkpI9mb3FuIAvUtpWRRMU0320QHVuuSC00O0uYsw2hY6B9h2NY4-PeDGuj7EhEODF7C2ve99wpd49HFIOEJ2_ZjV0GHf4cmHrk944_sFTqH1Ne6H1TT_pETI2gg1vr78lfkG3DR5jN42tk3w_vk-Qj-_XP2YX89ubr9-m1_czBznZTETZUVZVXFZV5YT4IxRILKqpRCWNFWtnWKlpA2hutRMl-BqKQnRjCvKoVHsCH3e5q6HagW1y5tG25p19CsbH02w3rx0Or8w92E0iikticgBn54DYvg9QOrNyicHbWs7CEMytJCKMEq5zOjH_9BlGGKXv2cokaXKkSXL1OmWcjGkFKHZLUMKM_Vppj7NU58Z_vDv-jv0b4EZIFtg41t4fCXKXHyf325D_wAlgKyP</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2168773783</pqid></control><display><type>article</type><title>Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Kotake, Takeshi ; Satake, Hironaga ; Okita, Yoshihiro ; Hatachi, Yukimasa ; Hamada, Mamiko ; Omiya, Masatomo ; Yasui, Hisateru ; Hashida, Toru ; Kaihara, Satoshi ; Inokuma, Tetsuro ; Tsuji, Akihito</creator><creatorcontrib>Kotake, Takeshi ; Satake, Hironaga ; Okita, Yoshihiro ; Hatachi, Yukimasa ; Hamada, Mamiko ; Omiya, Masatomo ; Yasui, Hisateru ; Hashida, Toru ; Kaihara, Satoshi ; Inokuma, Tetsuro ; Tsuji, Akihito</creatorcontrib><description>Background
Reports of hepatitis B virus (HBV) reactivation in solid tumors are very limited, and their frequencies and risk factors were previously unknown.
Aim
To evaluate the prevalence and risk factors of HBV reactivation in patients with solid tumors with resolved HBV infection.
Methods
All 1088 patients with solid tumors were assessed for eligibility; 251 patients had resolved HBV infection (negative for HBs antigen and positive for anti‐HBc antibody and/or positive for anti‐HBs antibody), and HBV‐DNA was assessed for 243 of these patients in whom we analyzed the prevalence of HBV reactivation. Risk factors for HBV reactivation were exploratorily evaluated by analysis of a case–control study.
Results
The prevalence of HBV‐DNA reactivation was 2.1% (95% confidence interval [CI], 0.3–3.9%). We did not observe any exacerbation of HBV‐DNA by early intervention. A low anti‐HBs antibody titer (<10.0 mIU/mL) and high average daily dexamethasone dose (>1.0 mg/day) were high risk factors, with odds ratios of 5.94 (95% CI, 1.15–30.6, P = 0.03) and 8.69 (95% CI, 1.27–58.8, P = 0.02), respectively.
Conclusion
HBV reactivation in solid tumor patients was relatively rare. Therefore, risk factors that can identify targets for HBV screening must be determined in future studies.</description><identifier>ISSN: 1743-7555</identifier><identifier>EISSN: 1743-7563</identifier><identifier>DOI: 10.1111/ajco.13050</identifier><identifier>PMID: 29984542</identifier><language>eng</language><publisher>Australia: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antiviral Agents - therapeutic use ; Case-Control Studies ; de novo hepatitis ; Deoxyribonucleic acid ; Dexamethasone ; DNA ; Female ; HBs antibody ; Health risk assessment ; Hepatitis ; Hepatitis B ; Hepatitis B - drug therapy ; Hepatitis B - epidemiology ; Hepatitis B - virology ; Hepatitis B virus - drug effects ; Humans ; Infections ; Japan - epidemiology ; Male ; Middle Aged ; Neoplasms - drug therapy ; Neoplasms - virology ; Original ; Prevalence ; resolved HBV infection ; Retrospective Studies ; Risk Factors ; solid tumor ; Solid tumors ; steroid ; Tumors ; Virus Activation - drug effects</subject><ispartof>Asia-Pacific journal of clinical oncology, 2019-02, Vol.15 (1), p.63-68</ispartof><rights>2018 The Authors. Published by John Wiley & Sons Australia, Ltd.</rights><rights>2018 The Authors. Asia-Pacific Journal of Clinical Oncology Published by John Wiley & Sons Australia, Ltd.</rights><rights>2019 John Wiley & Sons Australia, Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4480-58b23bb46dba41e4332e16bd655a1fbd9c73862f12989398ecd6611934724ef73</citedby><cites>FETCH-LOGICAL-c4480-58b23bb46dba41e4332e16bd655a1fbd9c73862f12989398ecd6611934724ef73</cites><orcidid>0000-0002-9426-2612</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fajco.13050$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fajco.13050$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29984542$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kotake, Takeshi</creatorcontrib><creatorcontrib>Satake, Hironaga</creatorcontrib><creatorcontrib>Okita, Yoshihiro</creatorcontrib><creatorcontrib>Hatachi, Yukimasa</creatorcontrib><creatorcontrib>Hamada, Mamiko</creatorcontrib><creatorcontrib>Omiya, Masatomo</creatorcontrib><creatorcontrib>Yasui, Hisateru</creatorcontrib><creatorcontrib>Hashida, Toru</creatorcontrib><creatorcontrib>Kaihara, Satoshi</creatorcontrib><creatorcontrib>Inokuma, Tetsuro</creatorcontrib><creatorcontrib>Tsuji, Akihito</creatorcontrib><title>Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection</title><title>Asia-Pacific journal of clinical oncology</title><addtitle>Asia Pac J Clin Oncol</addtitle><description>Background
Reports of hepatitis B virus (HBV) reactivation in solid tumors are very limited, and their frequencies and risk factors were previously unknown.
Aim
To evaluate the prevalence and risk factors of HBV reactivation in patients with solid tumors with resolved HBV infection.
Methods
All 1088 patients with solid tumors were assessed for eligibility; 251 patients had resolved HBV infection (negative for HBs antigen and positive for anti‐HBc antibody and/or positive for anti‐HBs antibody), and HBV‐DNA was assessed for 243 of these patients in whom we analyzed the prevalence of HBV reactivation. Risk factors for HBV reactivation were exploratorily evaluated by analysis of a case–control study.
Results
The prevalence of HBV‐DNA reactivation was 2.1% (95% confidence interval [CI], 0.3–3.9%). We did not observe any exacerbation of HBV‐DNA by early intervention. A low anti‐HBs antibody titer (<10.0 mIU/mL) and high average daily dexamethasone dose (>1.0 mg/day) were high risk factors, with odds ratios of 5.94 (95% CI, 1.15–30.6, P = 0.03) and 8.69 (95% CI, 1.27–58.8, P = 0.02), respectively.
Conclusion
HBV reactivation in solid tumor patients was relatively rare. Therefore, risk factors that can identify targets for HBV screening must be determined in future studies.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Case-Control Studies</subject><subject>de novo hepatitis</subject><subject>Deoxyribonucleic acid</subject><subject>Dexamethasone</subject><subject>DNA</subject><subject>Female</subject><subject>HBs antibody</subject><subject>Health risk assessment</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis B - drug therapy</subject><subject>Hepatitis B - epidemiology</subject><subject>Hepatitis B - virology</subject><subject>Hepatitis B virus - drug effects</subject><subject>Humans</subject><subject>Infections</subject><subject>Japan - epidemiology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - virology</subject><subject>Original</subject><subject>Prevalence</subject><subject>resolved HBV infection</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>solid tumor</subject><subject>Solid tumors</subject><subject>steroid</subject><subject>Tumors</subject><subject>Virus Activation - drug effects</subject><issn>1743-7555</issn><issn>1743-7563</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp9kc1O3DAUhS3UCih0wwNUlrqpkAbi_3hTCUa0tEKCRdut5Tg3jIdMPLWTjHj7OgwdlS7wxtY53z261kHohBRnJJ9zu3ThjLBCFHvokCjOZkpI9mb3FuIAvUtpWRRMU0320QHVuuSC00O0uYsw2hY6B9h2NY4-PeDGuj7EhEODF7C2ve99wpd49HFIOEJ2_ZjV0GHf4cmHrk944_sFTqH1Ne6H1TT_pETI2gg1vr78lfkG3DR5jN42tk3w_vk-Qj-_XP2YX89ubr9-m1_czBznZTETZUVZVXFZV5YT4IxRILKqpRCWNFWtnWKlpA2hutRMl-BqKQnRjCvKoVHsCH3e5q6HagW1y5tG25p19CsbH02w3rx0Or8w92E0iikticgBn54DYvg9QOrNyicHbWs7CEMytJCKMEq5zOjH_9BlGGKXv2cokaXKkSXL1OmWcjGkFKHZLUMKM_Vppj7NU58Z_vDv-jv0b4EZIFtg41t4fCXKXHyf325D_wAlgKyP</recordid><startdate>201902</startdate><enddate>201902</enddate><creator>Kotake, Takeshi</creator><creator>Satake, Hironaga</creator><creator>Okita, Yoshihiro</creator><creator>Hatachi, Yukimasa</creator><creator>Hamada, Mamiko</creator><creator>Omiya, Masatomo</creator><creator>Yasui, Hisateru</creator><creator>Hashida, Toru</creator><creator>Kaihara, Satoshi</creator><creator>Inokuma, Tetsuro</creator><creator>Tsuji, Akihito</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9426-2612</orcidid></search><sort><creationdate>201902</creationdate><title>Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection</title><author>Kotake, Takeshi ; Satake, Hironaga ; Okita, Yoshihiro ; Hatachi, Yukimasa ; Hamada, Mamiko ; Omiya, Masatomo ; Yasui, Hisateru ; Hashida, Toru ; Kaihara, Satoshi ; Inokuma, Tetsuro ; Tsuji, Akihito</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4480-58b23bb46dba41e4332e16bd655a1fbd9c73862f12989398ecd6611934724ef73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Case-Control Studies</topic><topic>de novo hepatitis</topic><topic>Deoxyribonucleic acid</topic><topic>Dexamethasone</topic><topic>DNA</topic><topic>Female</topic><topic>HBs antibody</topic><topic>Health risk assessment</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis B - drug therapy</topic><topic>Hepatitis B - epidemiology</topic><topic>Hepatitis B - virology</topic><topic>Hepatitis B virus - drug effects</topic><topic>Humans</topic><topic>Infections</topic><topic>Japan - epidemiology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - virology</topic><topic>Original</topic><topic>Prevalence</topic><topic>resolved HBV infection</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>solid tumor</topic><topic>Solid tumors</topic><topic>steroid</topic><topic>Tumors</topic><topic>Virus Activation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kotake, Takeshi</creatorcontrib><creatorcontrib>Satake, Hironaga</creatorcontrib><creatorcontrib>Okita, Yoshihiro</creatorcontrib><creatorcontrib>Hatachi, Yukimasa</creatorcontrib><creatorcontrib>Hamada, Mamiko</creatorcontrib><creatorcontrib>Omiya, Masatomo</creatorcontrib><creatorcontrib>Yasui, Hisateru</creatorcontrib><creatorcontrib>Hashida, Toru</creatorcontrib><creatorcontrib>Kaihara, Satoshi</creatorcontrib><creatorcontrib>Inokuma, Tetsuro</creatorcontrib><creatorcontrib>Tsuji, Akihito</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Asia-Pacific journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kotake, Takeshi</au><au>Satake, Hironaga</au><au>Okita, Yoshihiro</au><au>Hatachi, Yukimasa</au><au>Hamada, Mamiko</au><au>Omiya, Masatomo</au><au>Yasui, Hisateru</au><au>Hashida, Toru</au><au>Kaihara, Satoshi</au><au>Inokuma, Tetsuro</au><au>Tsuji, Akihito</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection</atitle><jtitle>Asia-Pacific journal of clinical oncology</jtitle><addtitle>Asia Pac J Clin Oncol</addtitle><date>2019-02</date><risdate>2019</risdate><volume>15</volume><issue>1</issue><spage>63</spage><epage>68</epage><pages>63-68</pages><issn>1743-7555</issn><eissn>1743-7563</eissn><abstract>Background
Reports of hepatitis B virus (HBV) reactivation in solid tumors are very limited, and their frequencies and risk factors were previously unknown.
Aim
To evaluate the prevalence and risk factors of HBV reactivation in patients with solid tumors with resolved HBV infection.
Methods
All 1088 patients with solid tumors were assessed for eligibility; 251 patients had resolved HBV infection (negative for HBs antigen and positive for anti‐HBc antibody and/or positive for anti‐HBs antibody), and HBV‐DNA was assessed for 243 of these patients in whom we analyzed the prevalence of HBV reactivation. Risk factors for HBV reactivation were exploratorily evaluated by analysis of a case–control study.
Results
The prevalence of HBV‐DNA reactivation was 2.1% (95% confidence interval [CI], 0.3–3.9%). We did not observe any exacerbation of HBV‐DNA by early intervention. A low anti‐HBs antibody titer (<10.0 mIU/mL) and high average daily dexamethasone dose (>1.0 mg/day) were high risk factors, with odds ratios of 5.94 (95% CI, 1.15–30.6, P = 0.03) and 8.69 (95% CI, 1.27–58.8, P = 0.02), respectively.
Conclusion
HBV reactivation in solid tumor patients was relatively rare. Therefore, risk factors that can identify targets for HBV screening must be determined in future studies.</abstract><cop>Australia</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29984542</pmid><doi>10.1111/ajco.13050</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-9426-2612</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1743-7555 |
| ispartof | Asia-Pacific journal of clinical oncology, 2019-02, Vol.15 (1), p.63-68 |
| issn | 1743-7555 1743-7563 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7379615 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Aged, 80 and over Antiviral Agents - therapeutic use Case-Control Studies de novo hepatitis Deoxyribonucleic acid Dexamethasone DNA Female HBs antibody Health risk assessment Hepatitis Hepatitis B Hepatitis B - drug therapy Hepatitis B - epidemiology Hepatitis B - virology Hepatitis B virus - drug effects Humans Infections Japan - epidemiology Male Middle Aged Neoplasms - drug therapy Neoplasms - virology Original Prevalence resolved HBV infection Retrospective Studies Risk Factors solid tumor Solid tumors steroid Tumors Virus Activation - drug effects |
| title | Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T21%3A27%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20and%20risk%20factors%20of%20hepatitis%20B%20virus%20reactivation%20in%20patients%20with%20solid%20tumors%20with%20resolved%20HBV%20infection&rft.jtitle=Asia-Pacific%20journal%20of%20clinical%20oncology&rft.au=Kotake,%20Takeshi&rft.date=2019-02&rft.volume=15&rft.issue=1&rft.spage=63&rft.epage=68&rft.pages=63-68&rft.issn=1743-7555&rft.eissn=1743-7563&rft_id=info:doi/10.1111/ajco.13050&rft_dat=%3Cproquest_pubme%3E2067132246%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2168773783&rft_id=info:pmid/29984542&rfr_iscdi=true |